Track topics on Twitter Track topics that are important to you
JACKSONVILLE, Fla., Aug. 10, 2015 (GLOBE NEWSWIRE) -- ParkerVision, Inc. (NASDAQ:PRKR), a developer and marketer of semiconductor technology solutions for wireless applications, today announced results for the three and six months ended June 30, 2015.
Second Quarter 2015 Business Highlights and Recent Developments
Jeffrey Parker, Chairman and Chief Executive Officer, commented, "We disagree with the appellate court's decision with regard to our patent infringement action against Qualcomm, and we intend to pursue a rehearing with the appellate court. We remain steadfast in our knowledge that our patent portfolio is a valuable asset and that these patented innovations can generate meaningful licensing and product revenue. We continue to see expanding interest in our products and services, and our litigation, licensing and funding partners are undeterred as they continue to work with us on the next steps towards enforcing our intellectual property rights and recognizing the value for those rights."
Second Quarter and First Half 2015 Financial Results
The Company will host a conference call and webcast on August 10, 2015 at 4:30 p.m. Eastern to review its second quarter 2015 financial results. The conference call will be accessible by telephone at 1-877-561-2750, at least five minutes before the scheduled start time. International callers should dial 763-416-8565. The conference call may also be accessed by means of a live webcast on our website at http://ir.parkervision.com/events.cfm. The conference webcast will also be archived and available for replay on our website at www.parkervision.com for a period of 90 days.
ParkerVision, Inc. designs, develops and markets its proprietary radio-frequency (RF) technologies that enable advanced wireless solutions for current and next generation communications networks. Protected by a highly-regarded, worldwide patent portfolio, the Company's solutions for wireless transfer of RF waveforms address the needs of a broad range of wirelessly connected devices for high levels of RF performance coupled with best-in-class power consumption. For more information please visit www.parkervision.com. (PRKR-I)
Safe Harbor Statement
This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports, including the Form 10K for the year ended December 31, 2014 and the Form 10Q for the quarter ended March 31, 2015 and June 30, 2015. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.
|Summary of Results of Operations (unaudited)|
|Three Months Ended||Six Months Ended|
|(in thousands, except per share amounts)||June 30,||June 30,|
|Revenue||$ 0||$ 0||$ 0||$ 0|
|Cost of sales||0||0||0||0|
|Research and development expenses||1,694||2,241||3,452||4,505|
|Marketing and selling expenses||390||788||876||1,445|
|General and administrative expenses||2,750||2,846||6,293||5,719|
|Total operating expenses||4,834||5,875||10,621||11,669|
|Interest and other income and interest expense||(8)||34||3||56|
|Net loss||$ (4,842)||$ (5,841)||$ (10,618)||$ (11,613)|
|Basic and diluted net loss per common share||$ (0.05)||$ (0.06)||$ (0.11)||$ (0.12)|
|Weighted average shares outstanding||97,645||96,999||97,543||95,360|
|Balance Sheet Highlights (in thousands)|
|June 30, 2015||December 31,|
|Cash and available-for-sale securities||$ 3,980||$ 11,204|
|Accounts receivable, net||20||0|
|Prepaid and other assets||593||813|
|Property and equipment, net||704||633|
|Intangible assets, net||7,913||8,003|
|Total liabilities and shareholders' equity||$ 13,334||$ 20,719|
CONTACT: Cindy Poehlman Chief Financial Officer ParkerVision, Inc 904-732-6100, firstname.lastname@example.org Don Markley or Glenn Garmont The Piacente Group 212-481-2050, email@example.comNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...